ALS INVESTMENT FUND
We invest in biotech companies developing drugs in a specialized area of disease: neurodegeneration, with a particular focus in ALS.
NICHE INVESTMENT WITH A BROAD REACH
We are a highly specialized biotech investor. We currently manage the largest and most diversified portfolio of ALS related companies worldwide. We are also globally among the most diversified VC funds in neurodegeneration in general with the ambition to build out this position. The knowledge we gather through our portfolio and our longstanding relationships with a global ALS-related network of scientists, clinicians, foundations, and patient advocates, differentiates us from other investors.
PORTFOLIO
TEAM
-
Felix von Coerper
MANAGING PARTNER
-
Melanie Leitner
CHIEF SCIENTIFIC OFFICER. PARTNER
-
Craig Boyce
MANAGING PARTNER
-
Rist Brouwer
ADVISOR
ADVISORS
-
Dr. Robert Brown
UMASS (USA)
-
Dr. Kuldip Dave
VP R&D ALSA (USA)
-
Dr. Merit Cudkowicz
MGH/HARVARD (USA)
-
Prof. Leonard van den Berg
UMC UTRECHT (NL)
-
Dr. Fernando Vieira
ALS TDI (USA)
-
Dr. Alan Walts